Suppr超能文献

第六个十年患有机械和生物主动脉假体的患者的中期生存情况。

Medium-term survival of patients with mechanical and biological aortic prosthesis at the 6th decade of life.

机构信息

Centro Cardiovascular Universitario, Hospital de Clinicas, Universidad de la Republica, Montevideo, Uruguay.

Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.

出版信息

PLoS One. 2024 Nov 18;19(11):e0312408. doi: 10.1371/journal.pone.0312408. eCollection 2024.

Abstract

OBJECTIVE

The best aortic prosthesis type in 60-70 year old patients is not established. Our aim was to evaluate the survival in a National cohort of patients between 60-70 years old who required surgical aortic valve replacement for aortic stenosis (SAVR) with either a mechanical (MP) or bioprosthesis (BP) valve.

METHODS

This is a retrospective study using national data from the Ministry of Health. We included all patients between 60 to 70 years old who underwent SAVR for aortic stenosis in Uruguay from 2011 to 2021. The primary outcome was overall survival according to type of prosthesis used stratified by effect modifiers. The independent effects of gender and use of statins were evaluated.

RESULTS

We included 1196 patients (66±3.0 years old; 39.1% female). Mortality was higher for BP (296, 29.9%%) than MP (36, 17.1%; p<0.001). Median follow-up time was 4.5 years (Interquartile range [IQR] 3.4-6.5). The unadjusted incidence rate ratio was higher for BP (Incidence rate ratio [IRR] = 1.43;95%CI: 0.99, 2.14, p = 0.045). The effect of BP on mortality rate was greater in males (IRR = 1.82;95%CI:1.14,2.92. p interaction = 0.08) and patients who were not taking statins (IRR = 1.97;95%CI:1.14,3.41. p interaction = 0.06). The use of BP was an independent predictor of overall survival in male patients (Hazard ratio [HR] = 1.32;95%CI: 1.68, 1.04. p = 0.021) and in patients who were not taking statins (HR = 2.07;95%CI: 1.17, 3.67. p = 0.013).

CONCLUSION

The use of BP was associated with worse survival in male patients and patients not taking statins. Gender and statins use should contribute to type of prosthesis decision in the 60-69 age group.

摘要

目的

在 60-70 岁的患者中,哪种主动脉假体最好尚未确定。我们的目的是评估在乌拉圭 2011 年至 2021 年期间,60-70 岁因主动脉瓣狭窄(SAVR)需要行主动脉瓣置换术(SAVR)的患者中,使用机械(MP)或生物(BP)瓣膜的患者的生存情况。

方法

这是一项使用卫生部国家数据的回顾性研究。我们纳入了所有 60 至 70 岁之间因主动脉瓣狭窄接受 SAVR 的患者。主要结局是根据使用的假体类型,分层考虑校正变量后患者的总体生存率。评估了性别和使用他汀类药物的独立影响。

结果

我们纳入了 1196 名患者(66±3.0 岁;39.1%为女性)。BP(296 例,29.9%)的死亡率高于 MP(36 例,17.1%;p<0.001)。中位随访时间为 4.5 年(四分位间距[IQR]3.4-6.5)。BP 的未校正发病率比值更高(发病率比值[IRR] = 1.43;95%CI:0.99,2.14,p = 0.045)。BP 对死亡率的影响在男性(IRR = 1.82;95%CI:1.14,2.92. p 交互= 0.08)和未服用他汀类药物的患者中更大(IRR = 1.97;95%CI:1.14,3.41. p 交互= 0.06)。在男性患者(危险比[HR] = 1.32;95%CI:1.68,1.04. p = 0.021)和未服用他汀类药物的患者(HR = 2.07;95%CI:1.17,3.67. p = 0.013)中,BP 的使用是总生存的独立预测因子。

结论

在男性患者和未服用他汀类药物的患者中,BP 的使用与生存质量下降相关。性别和他汀类药物的使用应该有助于在 60-69 岁年龄组中选择假体类型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c813/11573135/5682782d19e8/pone.0312408.g001.jpg

相似文献

1
Medium-term survival of patients with mechanical and biological aortic prosthesis at the 6th decade of life.
PLoS One. 2024 Nov 18;19(11):e0312408. doi: 10.1371/journal.pone.0312408. eCollection 2024.
3
Age-Based Outcomes After Surgical Aortic Valve Replacement With Bioprosthetic Versus Mechanical Valves.
Am J Cardiol. 2024 Sep 1;226:72-79. doi: 10.1016/j.amjcard.2024.07.004. Epub 2024 Jul 10.
6
Transcatheter or Surgical Replacement for Failed Bioprosthetic Aortic Valves.
JAMA Cardiol. 2024 Jul 1;9(7):631-639. doi: 10.1001/jamacardio.2024.1049.
9
Long-Term Outcomes Following Surgical Aortic Bioprosthesis Implantation.
J Am Coll Cardiol. 2018 Apr 3;71(13):1401-1412. doi: 10.1016/j.jacc.2018.01.059.
10
Transcatheter aortic valve implantation in failed bioprosthetic surgical valves.
JAMA. 2014 Jul;312(2):162-70. doi: 10.1001/jama.2014.7246.

引用本文的文献

1
Comparative evaluation of mechanical and biological prostheses in patients with aortic stenosis.
Interdiscip Cardiovasc Thorac Surg. 2025 May 6;40(5). doi: 10.1093/icvts/ivaf091.

本文引用的文献

1
Aortic Valve Replacement With Mechanical Valves vs Perimount Bioprostheses in 50- to 69-Year-Old Patients.
JACC Adv. 2023 Jun 7;2(4):100359. doi: 10.1016/j.jacadv.2023.100359. eCollection 2023 Jun.
5
Mechanical aortic valve prostheses offer a survival benefit in 50-65 year olds: AUTHEARTVISIT study.
Eur J Clin Invest. 2022 May;52(5):e13736. doi: 10.1111/eci.13736. Epub 2021 Dec 30.
6
2021 ESC/EACTS Guidelines for the management of valvular heart disease.
Eur Heart J. 2022 Feb 12;43(7):561-632. doi: 10.1093/eurheartj/ehab395.
7
Similar long-term survival after isolated bioprosthetic versus mechanical aortic valve replacement: A propensity-matched analysis.
J Thorac Cardiovasc Surg. 2022 Nov;164(5):1444-1455.e4. doi: 10.1016/j.jtcvs.2020.11.181. Epub 2021 Jan 20.
8
Sex Differences in Long-Term Outcomes After Surgical Aortic Valve Replacement: A Nationwide Propensity-matched Study.
J Cardiothorac Vasc Anesth. 2020 Apr;34(4):932-939. doi: 10.1053/j.jvca.2019.10.011. Epub 2019 Oct 11.
9
Rosuvastatin attenuates bioprosthetic heart valve calcification.
J Thorac Cardiovasc Surg. 2019 Sep;158(3):731-741.e1. doi: 10.1016/j.jtcvs.2018.12.042. Epub 2019 Jan 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验